Cargando…
Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
[Image: see text] Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDM...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198280/ https://www.ncbi.nlm.nih.gov/pubmed/30216042 http://dx.doi.org/10.1021/acschembio.8b00665 |
_version_ | 1783364937327837184 |
---|---|
author | Stefaniak, Jakub Lewis, Andrew M. Conole, Daniel Galan, Sébastien R. G. Bataille, Carole J. R. Wynne, Graham M. Castaldi, M. Paola Lundbäck, Thomas Russell, Angela J. Huber, Kilian V. M. |
author_facet | Stefaniak, Jakub Lewis, Andrew M. Conole, Daniel Galan, Sébastien R. G. Bataille, Carole J. R. Wynne, Graham M. Castaldi, M. Paola Lundbäck, Thomas Russell, Angela J. Huber, Kilian V. M. |
author_sort | Stefaniak, Jakub |
collection | PubMed |
description | [Image: see text] Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDMX antagonists is still limited. The arylmethylidenepyrazolinone SJ-172550 has been reported as a selective MDMX antagonist; yet, uncertainties about its mechanism of action have raised doubts about its use as a chemical probe. Here, we show that, in addition to its unclear mode of action, SJ-172550 is unstable in aqueous buffers, giving rise to side products of unknown biological activity. Using an SJ-172550-derived affinity probe, we observed promiscuous binding to cellular proteins whereas cellular thermal shift assays did not reveal a stabilizing effect on MDMX. Overall, our results raise further questions about the interpretation of data using SJ-172550 and related compounds to investigate cellular phenotypes. |
format | Online Article Text |
id | pubmed-6198280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-61982802018-10-24 Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors Stefaniak, Jakub Lewis, Andrew M. Conole, Daniel Galan, Sébastien R. G. Bataille, Carole J. R. Wynne, Graham M. Castaldi, M. Paola Lundbäck, Thomas Russell, Angela J. Huber, Kilian V. M. ACS Chem Biol [Image: see text] Targeting the protein–protein interaction between p53 and MDM2/MDMX (MDM4) represents an attractive anticancer strategy for the treatment of p53-competent tumors. Several selective and potent MDM2 inhibitors have been developed and entered the clinic; however, the repertoire of MDMX antagonists is still limited. The arylmethylidenepyrazolinone SJ-172550 has been reported as a selective MDMX antagonist; yet, uncertainties about its mechanism of action have raised doubts about its use as a chemical probe. Here, we show that, in addition to its unclear mode of action, SJ-172550 is unstable in aqueous buffers, giving rise to side products of unknown biological activity. Using an SJ-172550-derived affinity probe, we observed promiscuous binding to cellular proteins whereas cellular thermal shift assays did not reveal a stabilizing effect on MDMX. Overall, our results raise further questions about the interpretation of data using SJ-172550 and related compounds to investigate cellular phenotypes. American Chemical Society 2018-09-14 2018-10-19 /pmc/articles/PMC6198280/ /pubmed/30216042 http://dx.doi.org/10.1021/acschembio.8b00665 Text en Copyright © 2018 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | Stefaniak, Jakub Lewis, Andrew M. Conole, Daniel Galan, Sébastien R. G. Bataille, Carole J. R. Wynne, Graham M. Castaldi, M. Paola Lundbäck, Thomas Russell, Angela J. Huber, Kilian V. M. Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors |
title | Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based
MDMX Inhibitors |
title_full | Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based
MDMX Inhibitors |
title_fullStr | Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based
MDMX Inhibitors |
title_full_unstemmed | Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based
MDMX Inhibitors |
title_short | Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based
MDMX Inhibitors |
title_sort | chemical instability and promiscuity of arylmethylidenepyrazolinone-based
mdmx inhibitors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198280/ https://www.ncbi.nlm.nih.gov/pubmed/30216042 http://dx.doi.org/10.1021/acschembio.8b00665 |
work_keys_str_mv | AT stefaniakjakub chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT lewisandrewm chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT conoledaniel chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT galansebastienrg chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT bataillecarolejr chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT wynnegrahamm chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT castaldimpaola chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT lundbackthomas chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT russellangelaj chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors AT huberkilianvm chemicalinstabilityandpromiscuityofarylmethylidenepyrazolinonebasedmdmxinhibitors |